LBL-007 + bevacizumab + fluoropyrimidine

LBL-007 + bevacizumab + fluoropyrimidine is a combination regimen under investigation for the treatment of advanced malignant tumors, including nasopharyngeal carcinoma and other solid tumors. - **LBL-007** is a monoclonal antibody targeting lymphocyte activation gene-3 (LAG-3), functioning as an immune checkpoint inhibitor to enhance T-cell mediated antitumor immunity. - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), suppressing tumor angiogenesis. - **Fluoropyrimidines** (such as 5-fluorouracil) are small molecule cytotoxic antimetabolites that interfere with DNA synthesis to induce cell death in proliferating tumor cells. This regimen represents a combination of immunotherapy (checkpoint inhibition) and chemotherapy plus antiangiogenic therapy, aiming to improve response rates and progression-free survival in cancers for which these components have shown individual efficacy[2][5][6].

Other names

5-fluorouracil